ANX Mast Therapeutics, Inc.

SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that its abstract was accepted for an oral presentation at the 14th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) program. The abstract outlines preclinical results demonstrating broad antiviral activity of Thiovir against multiple subtypes of avian and human influenza A and human influenza B virus, two types of herpes simplex virus, HSV-1 and HSV-2, and multiple HIV strains. The abstract is entitled "Thiovir exhibits broad-spectrum antiviral activity against human and avian influenza viruses, human immunodeficiency viruses, and herpes simplex viruses". Shani Waninger, Ph.D., associate director for research and development for ADVENTRX and lead author on the abstract, will deliver the talk on Thursday, June 22 in the "new antiretroviral drugs" plenary session. The ISHEID conference takes place June 21-23, 2006 in Toulon, France. For more information, visit the conference web site at http://www.isheid.com/. "We look forward to announcing these results demonstrating Thiovir activity against a range of viruses including herpes and influenza," said Dr. Waninger. "In addition to the work that will be presented at the ISHEID conference, results are forthcoming from ongoing Thiovir preclinical experiments." ADVENTRX currently plans to file an investigational new drug application (IND) with the US Food and Drug Administration (FDA) in order to initiate a Phase I/II clinical trial using Thiovir to treat HIV/AIDS in 2006. In addition, the Company is currently investigating development options for Thiovir to treat herpes infections and as a potential treatment for avian influenza. About Thiovir Thiovir is a broad spectrum antiviral drug that has been shown in preclinical tests to inhibit HIV, influenza A and herpes viruses. Thiovir is a pyrophosphate analogue reverse transcriptase inhibitor designed for oral delivery as a component of highly active antiretroviral therapy (HAART) for HIV/AIDS. Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet). About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at http://www.adventrx.com/. Forward-Looking Statement This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last annual report on Form 10-K, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site: http://www.isheid.com/ Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html

Copyright